The Life Sciences Report

"INO continues to advance multiple early-stage studies forward which should provide incremental catalysts as data emerges."

–Jason McCarthy, Maxim Group

"INO's DNA-based Zika Vaccine Phase 1 trial results demonstrate GLS-5700's potential efficacy in preventing Zika virus infection in human together with a solid safety profile."

–Ram Selvaraju, H.C. Wainwright & Co.

RP's Phase 1/2a trial for tendon repair in chronic Achilles tendinosis met its goal and established a complete safety profile at six months that showed no serious adverse events."

–The Life Sciences Report Interview with Colin Lee Novick

"While we view the Indivior deal positively as DRRX is able to gain exposure to a late-stage asset in a lucrative deal, we remain focused on Phase 3 PERSIST data expected Q4/17."

–Adam Walsh, Stifel

"We think the patent purchase agreement is a great deal for DRRX."

–Grant Zeng, Zacks Equity Research

"DRRX has received an upfront payment of $12.5 million, and is also eligible for $5 million in the event of FDA approval for Indivior's RBP-7000."

–Patrick Dolezal, LifeSci Advisors

"INO announced the publication of two preclinical studies of the company's plasmid DNA-encoded monoclonal antibody constructs in treating cancer and preventing infection from a pneumonia-causing bacteria."

–Ram Selvaraju, H.C. Wainwright & Co.

"RP is currently in discussions with potential partnerships focused not just on the firm's injector, but also on its regenerative medicine therapies."

–Douglas Loe, Echelon Wealth Partners

"PMN announced that a third therapy has been identified for the firm's Alzheimer's disease pipeline."

–Douglas Loe, Echelon Wealth Partners

"INO announced positive (Phase 1b) data for INO-5150."

–Jason McCarthy, Maxim Group

"INO's INO-5150 generated T-cell responses in 60% of trial subjects."

–Ram Selvaraju, H.C. Wainwright & Co.

"One of the major operational items of interest since VIVE's Q1 update is an agreement with InControl Medical LLC."

–Brian Marckx, Zacks Equity Research

"RP announced its participation in the ThawSTAR Early Adopter Program."

–Douglas Loe, Echelon Wealth Partners

"DRRX confirmed that it expects to complete patient follow-up visits this quarter, and announce top-line results from the Phase 3 PERSIST study in 4Q17."

–Ed Arce, H.C. Wainwright & Co.

"We believe VIVE's Phase 3 trial is on track for a readout of data in mid-2019."

–Anthony Vendetti, Maxim Group

"We believe that VIVE is currently in discussion with the agency and that a formal IDE would be submitted in the coming months such that a study (VIVEVE II) would commence in late 2017."

–Jeff Cohen, Ladenburg Thalmann

"We continue to be optimistic about DRRX's story."

–Grant Zeng, Zacks Equity Research

"Highlights of DRRX's second quarter include reaching a commercialization agreement with Sandoz, completing enrollment of a pivotal Phase III trial for this asset, and completing drug-drug interaction studies and a Phase Ib trial for DUR-928."

–Patrick Dolezal, LifeSci Advisors

"INO initiated a phase III study to evaluate VGX-3100 for treatment of cervical dysplasia caused by human papillomavirus."

–Zacks Equity Research

"On the back of DRRX's solid deal with Sandoz and with more catalysts to come in 2017 such as Posimir Phase 3 readout in 4Q17 and IND filings for DUR-928, we see potential near-term upside."

–Francois Brisebois, Laidlaw & Company